Those aberrantly expressed piRNAs in breast cancer including piR-4987, piR-021285, piR-823, piR-932, piR-36712, piR-016658 and piR-016975 may held potential to be developed as biomarkers and/or therapeutic targets in breast cancer. This evidence concerns the gene PIR and breast cancer.